2 news items
Actinium Pharmaceuticals (ATNM) Reveals Promising Results from SIERRA Trial at EHA Congress
ATNM
BMRN
EXEL
17 Jun 24
favorable safety profile, significantly reducing the risks of sepsis and mucositis compared to traditional care, further advocating its role as a safer
MAIA Biotechnology (MAIA): Pioneering New Frontiers in NSCLC Treatment with THIO
BMRN
EXEL
GMAB
7 Jun 24
The primary objectives of the THIO-101 trial are to assess the safety and tolerability of THIO and its efficacy in terms of ORR. To date, THIO, combined
- Prev
- 1
- Next